Trial Profile
Randomized Phase II Study to Compare a Combination Therapy With Gemcitabine and Treosulfan Versus a Monotherapy as First-Line Chemotherapy for Patients With Metastatic Ocular Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Treosulfan (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 16 Mar 2007 Status change from recruiting to completed.
- 13 Nov 2005 New trial record.